Our study included 14 Phase I clinical trials and 131 relapse or refractory B cell malignancies patients (73 ALL patients, 27 CLL patients, and 31 lymphoma patients) received CD19-CAR T cell immunotherapy [2–16]. Here, CD19 is linked to lymphoma.